Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Rayzzeron Mar 22, 2018 5:14pm

243 Views

Post# 27764879

RE:don't see any insider sells

Nicolas Bourgeois did indeed sell 500,000 shares yesterday. I don't see it as a big deal. Here is some background:

Mr Bourgeois is the Executive VP Finance & Business Developement of Citagenix, a subsidiary of Antibe. He is also the co-founder of Citagenix. When Antibe purchased Citagenix Mr Bourgeois received 4,672,520 shares in Antibe. That was back in Oct 2015. This is the first time he sold any shares and it was only 10.7% of his holdings. And he still has 500,000 in options.

Bullboard Posts

Three mispriced stocks exposed to major market tailwinds